Joe, that IMClone ( or should that be IMaCrook?) information is heartening. I too am at the point where, as Wolf puts it so inelegantly for him:
< Good news somewhere soon would be a good thing.>
But, I am now asking myself, if we do not see FDA approval, for some time, can DMX survive?
Because if we do not get FDA approval, the attendant US up front monies will not be forthcoming.
Outside of North America, we are going nowhere with Pennsaid, imho.
The UK decision was not good news. I think that you have to be desperate to think otherwise.
In my view, and I believe that I expressed it at the time, it did not make sense for DMX to
appoint such a tiny UK company to distribute Pennsaid.
I don't know why DMX did this and I am not surprised that Provalis may not
have been able to meet DMX's targets whatever they were. At the time of the
appointment of Provalis, I understand that Rebecca Keeler said that
Provalis had won the right to distribute Pennsaid in competition with a
larger pharma distribution company but that DMX had made the right
decision in selecting a small UK company. I thought that she was wrong at the
time. I take no joy from this as it has wasted more than a year in
developing the market for Pennsaid in the UK and has lost a year's potential
sales for DMX in the UK.
It may also weaken DMX's negotiations for new distributors in other
territories as potential distributors may now have some doubts about
Pennsaid (and/or Dimethaid). Despite this experience in the UK, she has
repeated the same pattern of behavior by recently selecting other
small companies to distribute Pennsaid in other countries, e.g. the Netherlands grouping, Italy, Barbados.
This policy has not been explained clearly to DMX shareholders. I hope that she does not do the same in the US. All this talk about J&J but J&J were not appointed in any of these other agreements - and why not?
It is a mystery to me. Because, even if you can explain why J& J could not get involved at this point ( and that requires some contortions in logic) does any one of you have any insight or idea why she is repeating this
policy with other small distributors rather than selecting a Europe wide distributor? It is equivalent to selecting a different distributor for every state in the United States which would be stupid if it happened.
I think that Pennsaid has considerable commercial potential but, no matter how excellent the drug delivery system and the product is, it must be properly marketed to gain market share and earn sales and profits. If it is not marketed successfully then Pennsaid will be a commercial failure.
DMX has persevered through years of research and development at enormous cost and shareholders have shown immense patience but DMX seems to know little about marketing and does not seem willing to
appoint those who have the expertise to develop the market (not the product) and reward DMX's shareholders with profits and an increasing share price.
Maybe, it time to review the suitability of DMX management for the next stage of DMX's development as it moves from a research and development company into a main stream pharma marketing new
products.
I would be concerned that the fungal and WF10 commercial opportunities will also be missed in the pursuit of pure science.
Maybe the present team, who have shown excellence in developing Pennsaid and WF 10, are not the right team to make DMX profitable.
Why can DMX not sign up a world wide deal for Pennsaid similiar to the company
below instead of messing with tiny distributors in different countries?
Regards to all - this IS a great discussion group, with many individuals so generous with sharing their research and their opinions. I hope that these thoughts will generate an open discussion of my concerns. Fox.
PS let's all not forget that it was Jean C. who almost let the country slip away, at the time of the Quebec referendum.
CLOSURE Medical Corporation (NASDAQ: CLSR ) develops medical tissue
adhesive products based on its proprietary cyano-acrylate technology. The
company's medical tissue adhesive products align and seal injured tissue without
the trauma caused by suturing or stapling, allowing natural healing to proceed.
CLOSURE's lead product, DERMABOND, is a non-absorbable cohesive used to
seal wounds and incisions without the need for suturing or stapling. The company
has signed a worldwide supply, distribution and development rights agreement with
Johnson & Johnson, which includes rights to BAND-AID (R) Brand Liquid
Bandage products. BAND-AID Brand Liquid Bandage is painted on the wound,
sealing it from dirt and germs and creating a healing environment. Revenue for the
most recent fourth quarter increased over 50% to $6.0 million from $3.9 million in
the same year-earlier period. EPS in the latest quarter grew 700% to $0.08 vs.
$0.01 in the year-ago fourth quarter. |
